ALN-AGT01

DRUG2 trials

Sponsors

Alnylam Pharmaceuticals

Conditions

Hypertension

Phase 1

A Study to Evaluate ALN-AGT01 in Patients With Hypertension

CompletedNCT03934307

Alnylam PharmaceuticalsHypertension

Start: 2019-05-01End: 2023-01-04Updated: 2023-01-17

Phase 2

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

CompletedNCT04936035

Alnylam PharmaceuticalsHypertension

Start: 2021-07-07End: 2024-12-05Updated: 2025-12-23

Related Papers

Platform Assessment of Concentration-QTc Relationship Across GalNAc-siRNA Molecules.

2025-12-12

Abstract 4138847: Home Blood Pressure Reductions With Zilebesiran In Patients With Mild-To-Moderate Hypertension Are Consistent With Ambulatory And Office Blood Pressure Reductions In The KARDIA-1 Study

Circulation2024-11-121 citations

KARDIA-3 STUDY DESIGN: ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND HYPERTENSION INADEQUATELY CONTROLLED BY STANDARD OF CARE ANTIHYPERTENSIVES

Journal of Hypertension2024-05-018 citations

RNA Interference With Zilebesiran for Mild to Moderate Hypertension

JAMA2024-02-16100 citations

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

New England Journal of Medicine2023-07-19228 citations